Recent Updates — MJID

Ping An Biomedical Co., Ltd. entered into a definitive purchase agreement with Future Biotechnology Group Co., Limited on November 4, 2026, to acquire three tumor cell-related medical technology patents for an aggregate consideration of USD 2.3 million. The acquisition covers technologies in oncology diagnosis and treatment, cell detection, bioengineering, biomarkers, and DNA probes. This transaction follows a letter of intent dated October 22, 2026, and is intended to support the company's longer-term healthcare and biomedical research and development strategy by establishing a core intellectual property portfolio. The closing is subject to standard conditions. Ping An Biomedical Co., Ltd. operates as a supply chain management service provider in the apparel industry while pursuing innovative solutions in healthcare and biomedical technology.

The board of directors approved a one-for-forty reverse stock consolidation to be effective on October 23, 2026. The action reduces the outstanding share count from approximately 125 million combined Class A and B shares to roughly 3.1 million. Fractional entitlements will be rounded up rather than cashed out. This corporate action is designed to adjust the trading price of the company's Nasdaq-listed securities. Ping An Biomedical Co., Ltd. operates as a supply chain service provider in the apparel industry and delivers healthcare and biomedical technology solutions.